Imaging Based Dosimetry for Individualized Internal Emitter Therapy
| Status: | Completed |
|---|---|
| Conditions: | Lymphoma, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 5/19/2016 |
| Start Date: | June 2011 |
| End Date: | January 2016 |
The goal of this study is to develop imaging based methods to accurately determine the
energy absorbed (absorbed dose) by tumor tissue and bone marrow after radioimmunotherapy
with I-131 tositumomab . The administration of the radioactive, iodine-131 labeled,
monoclonal antibody I-131 tositumomab, (also known as Bexxar) is part of the patient's
clinical treatment protocol. For the absorbed dose measurement, investigators at the
University of Michigan are evaluating a new Nuclear Medicine SPECT/CT imaging system . This
new camera combines a CT imaging system in addition to a Nuclear Medicine SPECT scanner. CT
scans allow the doctors to see a high quality picture of your internal organs. The Nuclear
Medicine SPECT scanner allows the doctors to see the uptake of the radioactive I-131
including the tumor sites. The improved imaging using the SPECT/CT enables more accurate
calculation of the energy absorbed by tumor tissue and bone marrow. Using the results from
these calculations and clinical follow up data, the researchers will investigate the
relationship between the absorbed dose to the tumor and the patient's tumor response as well
as the relationship between the absorbed dose to the bone marrow and the bone marrow
toxicity. These relationships can potentially be used in the future by doctors to help
determine how much radioactive I-131 to administer to each patient to get optimal results.
energy absorbed (absorbed dose) by tumor tissue and bone marrow after radioimmunotherapy
with I-131 tositumomab . The administration of the radioactive, iodine-131 labeled,
monoclonal antibody I-131 tositumomab, (also known as Bexxar) is part of the patient's
clinical treatment protocol. For the absorbed dose measurement, investigators at the
University of Michigan are evaluating a new Nuclear Medicine SPECT/CT imaging system . This
new camera combines a CT imaging system in addition to a Nuclear Medicine SPECT scanner. CT
scans allow the doctors to see a high quality picture of your internal organs. The Nuclear
Medicine SPECT scanner allows the doctors to see the uptake of the radioactive I-131
including the tumor sites. The improved imaging using the SPECT/CT enables more accurate
calculation of the energy absorbed by tumor tissue and bone marrow. Using the results from
these calculations and clinical follow up data, the researchers will investigate the
relationship between the absorbed dose to the tumor and the patient's tumor response as well
as the relationship between the absorbed dose to the bone marrow and the bone marrow
toxicity. These relationships can potentially be used in the future by doctors to help
determine how much radioactive I-131 to administer to each patient to get optimal results.
Inclusion Criteria:
- • Clinically stable patients undergoing I-131 Tositumomab (Bexxar) for treatment of
Non-Hodgkin Lymphomas
Exclusion Criteria:
- • Clinical instability
- Patients who are unable to lie flat on the imaging systems long enough to permit
imaging protocols to be performed
- Refusal to provide informed consent
- Patients who are pregnant
We found this trial at
1
site
Click here to add this to my saved trials
